BioCryst study shows 30% drop in angioedema-related medical visits after switch to Orladeyo
BCRX•BioCryst Pharmaceuticals said two real-world studies found fewer healthcare visits among hereditary angioedema patients starting or switching to Orladeyo. The headline reports a 30% drop in angioedema-related medical visits after a switch.
1. Study findings
BioCryst Pharmaceuticals announced two real-world studies showing reduced healthcare use among hereditary angioedema patients starting or switching to Orladeyo. Patients switching from another preventive therapy had significantly fewer angioedema-related medical visits, while hospitalization reductions were not statistically significant. New preventive-treatment users had fewer emergency visits and hospitalizations, with no statistically significant differences between Orladeyo and comparator therapies. The results are scheduled for presentation November 13-14 at the American College of Allergy, Asthma & Immunology's 2026 annual meeting in Phoenix.
